Cancers Cell publishes Epizyme and collaborators’ breakthrough analysis on MLL Epizyme, Inc., a company leading the development and discovery of individualized therapeutics for genetically-defined tumor and rare disease individuals, and its own collaborators announced the publication in Cancer Cell of breakthrough research in the treating MLL-rearranged leukemia , a genetically-defined subset of acute lymphoblastic leukemia and severe myelogenous leukemia . This seminal research demonstrates for the very first time that a little molecule histone methyltransferase inhibitor can: selectively destroy genetically-described MLL tumors in vitro, with little influence on non-MLL leukemia cells, and drive a substantial anti-tumor survival benefit in an in vivo model statistically click to be linked .